Tirzepatide (Zepbound) for weight loss The bottom line Tirzepatide (Zepbound) was approved in 2023 by the US Food and Drug Administration (FDA) for weight loss
Either way, the drug enters circulation gradually rather than all at once
In addition, our pharmacy team supports patients and providers with clear communication, prescription fulfillment, and guidance related to the pharmacy process
Continued escalation and consistency lead to cumulative weight loss of 1522% of body weight over 612 months, depending on starting weight and lifestyle factors
However, evidence on the cardiovascular benefits of tirzepatide is only emerging and no randomized study has directly compared it to semaglutide 16,17
DOI: 10.1111/dom.70209 Jastreboff, A.M., et al